Mirum Pharmaceuticals vs PTC Therapeutics
MIRM and PTCT side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How MIRM and PTCT compare
Mirum Pharmaceuticals is the larger company, worth 1.2 times as much as PTC Therapeutics ($6.1B against $5.3B).
Mirum Pharmaceuticals grew revenue faster over the last twelve months (44.0% versus −35.1% for PTC Therapeutics).
PTC Therapeutics keeps more of each dollar of sales as profit, with a net margin of −9.2% compared with −139% at Mirum Pharmaceuticals.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | MIRM | PTCT |
|---|---|---|
| Size and price | ||
| Market cap | $6.1B | $5.3B |
| Share price | $93.99 | $63.49 |
| Change, 1 year | 32.8% | −15.3% |
| Change, 5 years | 499% | 58.7% |
| Beta (5Y) | 0.63 | 1.09 |
| Employees | 372 | 991 |
| StockData Score | ||
| Total score | 5 | 5 |
| Valuation score | 0 | 1 (better) |
| Growth score | 3 (better) | 1 |
| Performance score | 1 | 2 (better) |
| Health score | 1 | 1 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 9.9× | 4.6× (better) |
| EV/EBITDA | – | 17.8× |
| P/FCF | – | 2566× |
| FCF yield | −3.7% | 0.04% (better) |
| Fair value | – | $48.37 |
| Margin of safety | – | −31.3% |
| Growth | ||
| Revenue growth (TTM) | 44.0% (better) | −35.1% |
| Revenue growth, 5Y average | – | 35.4% |
| Net income growth (TTM) | – | −114% |
| EPS growth (TTM) | – | −114% |
| Profitability | ||
| Operating margin | −135% | 12.8% (better) |
| Net margin | −139% | −9.2% (better) |
| FCF margin | −37.0% | 0.18% (better) |
| Return on equity | −703% | – |
| Financial health | ||
| Net debt / EBITDA | – | −7.63 |
| Interest coverage | −62.1× | – |
| Current ratio | 2.86 | 3.27 (better) |
| Altman Z-score | −0.14 | 0.83 (better) |
| Piotroski F-score | 5 | 5 |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 110% | 120% |
| Held by insiders | 9.2% | 3.0% |
| Insider net buying, 12 months | −$31.5M (better) | −$44.2M |
| Short interest, % of float | 11.1% | 9.6% |
Go deeper
- MIRM stock overview
- MIRM income statement
- MIRM valuation and score
- PTCT stock overview
- PTCT income statement
- PTCT valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.